alnodesertib   Click here for help

GtoPdb Ligand ID: 13731

Synonyms: ART-0380 | ART0380 | compound 6 [PMID: 39630604] | example 39b [WO2019014618A1]
Compound class: Synthetic organic
Comment: The chemical structure for alnodesertib was derived from WHO proposed INN list 132 (Feb 2025). It is one of the ataxia telangiectasia and Rad3-related protein (ATR) kinase inhibitors claimed in patent WO2019014618A1 [2]. The SMILES for compound 39b provide a synonym match to ART0380 via PubChem. ART0380 is an oral ATR inhibitor that is intended as an anticancer drug [1]. Inhibiting ATR compounds the harmful effects of dyregulated DNA damage response (DDR) pathways in tumour cells.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 113.38
Molecular weight 388.49
XLogP 0.41
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C[C@@H]1COCCN1C2=CC(=NC(=N2)C3=CC=NC(=C3)N)N=[S@](=O)(C)C4CC4
Isomeric SMILES C[C@@H]1COCCN1C2=NC(=NC(=C2)N=[S@](=O)(C)C3CC3)C4=CC(=NC=C4)N
InChI InChI=1S/C18H24N6O2S/c1-12-11-26-8-7-24(12)17-10-16(23-27(2,25)14-3-4-14)21-18(22-17)13-5-6-20-15(19)9-13/h5-6,9-10,12,14H,3-4,7-8,11H2,1-2H3,(H2,19,20)/t12-,27+/m1/s1
InChI Key JHPDHYAMSPMBIF-MUDIAHQHSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Alnodesertib (ART0380) is being investigated for safety and efficacy as a treament for advanced solid tumours, as a monotherapy (in particular for tumours with confirmed DDR defects) and in combination with other DNA-damaging chemotherapeutics.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04657068 A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors Phase 1/Phase 2 Interventional Artios Pharma Ltd
NCT05798611 Study of ART0380 in Patients With Biologically Selected Solid Tumors Phase 2 Interventional Artios Pharma Ltd